Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19
December 27, 2021 07:00 ET
|
Pardes Biosciences, Inc
Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million,...
Pardes Biosciences Appoints New Chief Business and Strategy Officer
November 30, 2021 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to...
New Designers Space Introduces the VForce Collection: When Technology Meets Fashion
November 11, 2021 09:00 ET
|
New Designers Space
LOS ANGELES, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Los Angeles-based company, New Designers Space, has recognized the need for wearable technology to keep women and men safe & stylish. The...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
November 10, 2021 07:30 ET
|
Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021
October 28, 2021 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of...
Pardes Bioscience Announces Issuance of Its First U.S. Patent
September 21, 2021 16:05 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new...
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
September 16, 2021 08:30 ET
|
ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
September 02, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral...
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections
August 26, 2021 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the...